Generic placeholder image

Current Pharmaceutical Biotechnology


ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI

Author(s): Roberto Giugliani, Clarissa Gutierrez Carvalho, Silvani Herber and Louise Lapagesse de Camargo Pinto

Volume 12, Issue 6, 2011

Page: [956 - 972] Pages: 17

DOI: 10.2174/138920111795542688

Price: $65


Mucopolysaccharidosis VI is caused by accumulation of the glycosaminoglycan dermatan sulfate in all tissues due to decreased activity of the enzyme arylsulfatase B. Patients exhibit multisystemic signs and symptoms in a chronic and progressive manner, especially with changes in the skeleton, cardiopulmonary system, cornea, skin, liver, spleen and meninges. Patients usually have normal inteligence. In the past, treatment of mucopolysaccharidoses was limited to palliative medical care. The outcome for affected patients improved with the introduction of new technologies as hematopoietic stem cell transplantation, relegated to specific situations after enzyme replacement therapy (ERT) became available. The specific ERT for MPS VI, galsulfase (Naglazyme®, Biomarin Pharmaceutical) was approved in 2005 by FDA and in 2006 by EMEA, and three clinical studies including 56 patients have evaluated the efficacy and safety. Long-term follow up data with patients treated up to 5 years showed that ERT is well tolerated and associated with sustained improvements in the patients clinical condition. Intrathecal ERT may be considered in situations of high neurosurgical risk but still it is experimental in humans, as is intra-articular ERT. It is possible that the full impact of this therapy will only be demonstrated when patients are identified and treated soon after birth, as it was shown that early introduction of ERT produced immune tolerance and improved enzyme effectiveness in the cat model. New insights on the pathophysiology of MPS disorders are leading to alternative therapeutic approaches, as gene therapy, inflammatory response modulators and substrate reduction therapy.

Keywords: Mucopolysaccharidosis VI, Maroteaux-Lamy syndrome, glycosaminoglycans, lysosomal storage diseases, enzyme replacement therapy, therapy of genetic disorders, multisystemic signs and symptoms, hematopoietic stem cell transplantation, efficacy, neurosurgical risk, immune tolerance, gene therapy, inflammatory response, substrate reduction therapy

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy